Goldman Sachs Group set a €53.00 ($61.63) price objective on Fresenius SE & Co KGaA (FRA:FRE) in a research note released on Monday morning, Borsen Zeitung reports. The firm currently has a buy rating on the stock.

A number of other research analysts have also weighed in on FRE. Morgan Stanley set a €50.00 ($58.14) price objective on Fresenius SE & Co KGaA and gave the stock a neutral rating in a report on Wednesday, May 22nd. Nord/LB set a €58.00 ($67.44) target price on Fresenius SE & Co KGaA and gave the company a buy rating in a report on Wednesday, July 31st. Warburg Research set a €65.00 ($75.58) target price on Fresenius SE & Co KGaA and gave the company a buy rating in a report on Friday, July 26th. Berenberg Bank set a €74.80 ($86.98) target price on Fresenius SE & Co KGaA and gave the company a buy rating in a report on Monday, August 12th. Finally, Deutsche Bank set a €65.00 ($75.58) target price on Fresenius SE & Co KGaA and gave the company a buy rating in a report on Wednesday, July 31st. Nine investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Fresenius SE & Co KGaA has a consensus rating of Buy and a consensus target price of €58.48 ($68.00).

Fresenius SE & Co KGaA stock opened at €45.23 ($52.59) on Monday. Fresenius SE & Co KGaA has a 12 month low of €60.16 ($69.95) and a 12 month high of €80.00 ($93.02). The business has a 50 day simple moving average of €44.04 and a 200-day simple moving average of €47.38.

Fresenius SE & Co KGaA Company Profile

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Featured Article: What Are Cryptocurrencies?

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.